View in EDS

Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.

Saved in:
Bibliographic Details
Title: Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
Authors: Banerji A; Massachusetts General Hospital, Boston, Mass. Electronic address: abanerji@mgh.harvard.edu., Craig T; Department of Allergy, Asthma and Immunology, Penn State University, Hershey, Pa; VinMec/VinUniversity Institute of Immunology, Hanoi, Vietnam., Sitz K; Acuro Research Inc, Little Rock, Ark., Li HH; Institute for Asthma & Allergy, Chevy Chase, Md., Lumry W; Allergy and Asthma Research Associates, Dallas, Tex., Adatia A; University of Alberta, Edmonton, Alberta, Canada., Yang W; Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada., Jacobs JS; Allergy and Asthma Clinical Research, Walnut Creek, Calif., Tachdjian R; University of California-Los Angeles, Los Angeles, Calif., Soong W; AllerVie Health and Clinical Research, Birmingham, Ala., Manning M; Medical Research of Arizona, Scottsdale, Ariz., Wedner J; Washington University Physicians, St Louis, Mo., Savic S; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom., Manson A; Addenbrooke's Hospital, Cambridge, United Kingdom., Valerieva A; Medical University of Sofia, Sofia, Bulgaria., Gunsior M; Astria Therapeutics, Boston, Mass., Mugundu G; Astria Therapeutics, Boston, Mass., Cohen T; Astria Therapeutics, Boston, Mass., Bernard K; Astria Therapeutics, Boston, Mass., VanEenwyk C; Astria Therapeutics, Boston, Mass., Joseph K; Astria Therapeutics, Boston, Mass., Best JM; Astria Therapeutics, Boston, Mass., Morabito C; Astria Therapeutics, Boston, Mass., Riedl MA; University of California-San Diego, La Jolla, Calif.
Source: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2026 May; Vol. 157 (5), pp. 1127-1135.e6. Date of Electronic Publication: 2026 Mar 05.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41794053
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Banerji+A%22">Banerji A</searchLink>; Massachusetts General Hospital, Boston, Mass. Electronic address: abanerji@mgh.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Craig+T%22">Craig T</searchLink>; Department of Allergy, Asthma and Immunology, Penn State University, Hershey, Pa; VinMec/VinUniversity Institute of Immunology, Hanoi, Vietnam.<br /><searchLink fieldCode="AU" term="%22Sitz+K%22">Sitz K</searchLink>; Acuro Research Inc, Little Rock, Ark.<br /><searchLink fieldCode="AU" term="%22Li+HH%22">Li HH</searchLink>; Institute for Asthma & Allergy, Chevy Chase, Md.<br /><searchLink fieldCode="AU" term="%22Lumry+W%22">Lumry W</searchLink>; Allergy and Asthma Research Associates, Dallas, Tex.<br /><searchLink fieldCode="AU" term="%22Adatia+A%22">Adatia A</searchLink>; University of Alberta, Edmonton, Alberta, Canada.<br /><searchLink fieldCode="AU" term="%22Yang+W%22">Yang W</searchLink>; Ottawa Allergy Research Corporation, Ottawa, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Jacobs+JS%22">Jacobs JS</searchLink>; Allergy and Asthma Clinical Research, Walnut Creek, Calif.<br /><searchLink fieldCode="AU" term="%22Tachdjian+R%22">Tachdjian R</searchLink>; University of California-Los Angeles, Los Angeles, Calif.<br /><searchLink fieldCode="AU" term="%22Soong+W%22">Soong W</searchLink>; AllerVie Health and Clinical Research, Birmingham, Ala.<br /><searchLink fieldCode="AU" term="%22Manning+M%22">Manning M</searchLink>; Medical Research of Arizona, Scottsdale, Ariz.<br /><searchLink fieldCode="AU" term="%22Wedner+J%22">Wedner J</searchLink>; Washington University Physicians, St Louis, Mo.<br /><searchLink fieldCode="AU" term="%22Savic+S%22">Savic S</searchLink>; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Manson+A%22">Manson A</searchLink>; Addenbrooke's Hospital, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Valerieva+A%22">Valerieva A</searchLink>; Medical University of Sofia, Sofia, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Gunsior+M%22">Gunsior M</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Mugundu+G%22">Mugundu G</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Cohen+T%22">Cohen T</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Bernard+K%22">Bernard K</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22VanEenwyk+C%22">VanEenwyk C</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Joseph+K%22">Joseph K</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Best+JM%22">Best JM</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Morabito+C%22">Morabito C</searchLink>; Astria Therapeutics, Boston, Mass.<br /><searchLink fieldCode="AU" term="%22Riedl+MA%22">Riedl MA</searchLink>; University of California-San Diego, La Jolla, Calif.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%221275002%22">The Journal of allergy and clinical immunology</searchLink> [J Allergy Clin Immunol] 2026 May; Vol. 157 (5), pp. 1127-1135.e6. <i>Date of Electronic Publication: </i>2026 Mar 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mosby%22">Mosby </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>1275002 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-6825 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200916749%22">00916749 </searchLink><i>NLM ISO Abbreviation: </i>J Allergy Clin Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41794053
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaci.2026.02.034
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1127
    Titles:
      – TitleFull: Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Banerji A
      – PersonEntity:
          Name:
            NameFull: Craig T
      – PersonEntity:
          Name:
            NameFull: Sitz K
      – PersonEntity:
          Name:
            NameFull: Li HH
      – PersonEntity:
          Name:
            NameFull: Lumry W
      – PersonEntity:
          Name:
            NameFull: Adatia A
      – PersonEntity:
          Name:
            NameFull: Yang W
      – PersonEntity:
          Name:
            NameFull: Jacobs JS
      – PersonEntity:
          Name:
            NameFull: Tachdjian R
      – PersonEntity:
          Name:
            NameFull: Soong W
      – PersonEntity:
          Name:
            NameFull: Manning M
      – PersonEntity:
          Name:
            NameFull: Wedner J
      – PersonEntity:
          Name:
            NameFull: Savic S
      – PersonEntity:
          Name:
            NameFull: Manson A
      – PersonEntity:
          Name:
            NameFull: Valerieva A
      – PersonEntity:
          Name:
            NameFull: Gunsior M
      – PersonEntity:
          Name:
            NameFull: Mugundu G
      – PersonEntity:
          Name:
            NameFull: Cohen T
      – PersonEntity:
          Name:
            NameFull: Bernard K
      – PersonEntity:
          Name:
            NameFull: VanEenwyk C
      – PersonEntity:
          Name:
            NameFull: Joseph K
      – PersonEntity:
          Name:
            NameFull: Best JM
      – PersonEntity:
          Name:
            NameFull: Morabito C
      – PersonEntity:
          Name:
            NameFull: Riedl MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1097-6825
          Numbering:
            – Type: volume
              Value: 157
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The Journal of allergy and clinical immunology
              Type: main
ResultId 1